Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H19NO |
Molecular Weight | 241.3282 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(OC1CCNCC1)C2=CC3=C(C=CC=C3)C=C2
InChI
InChIKey=MJJDYOLPMGIWND-UHFFFAOYSA-N
InChI=1S/C16H19NO/c1-2-4-15-11-13(5-6-14(15)3-1)12-18-16-7-9-17-10-8-16/h1-6,11,16-17H,7-10,12H2
Molecular Formula | C16H19NO |
Molecular Weight | 241.3282 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Litoxetine is a selective serotonin (5-HT) reuptake inhibitor (SSRI) and mixed serotonin agonist-antagonist, which makes it particularly appropriate for treating continence dysfunctions. Litoxetine at concentrations without antimuscarinic properties (10 nM-1 microM) caused concentration-dependent relaxations in the rat isolated oesophageal muscularis mucosae, which reduced carbachol tone up to 37%. Higher litoxetine concentrations (3 microM-300 microM) were associated with marked relaxation up to the abolition of carbachol tone. The antimuscarinic activity of litoxetine, previously demonstrated in the isolated guinea-pig intestine, played a role in the rat isolated oesophageal muscularis mucosae at concentrations greater than 1 microM. The 5-HT-releasing action of litoxetine could account for the potentation by litoxetine of 5-HT-induced relaxation in tissues from untreated rats, which was reversed by pCPA treatment. Litoxetine is in phase II clinical trial for the treatment of urinary incontinence.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Anorectic activities of serotonin uptake inhibitors: correlation with their potencies at inhibiting serotonin uptake in vivo and 3H-mazindol binding in vitro. | 1988 |
|
A common binding site for tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitors at the substrate recognition site of the neuronal sodium-dependent 5-hydroxytryptamine transporter. | 1989 Nov 1 |
|
Advances in sodium-ion coupled biogenic amine transporters. | 1992 |
|
Activity of litoxetine and other serotonin uptake inhibitors in the tail suspension test in mice. | 1992 May |
|
Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. | 1993 Mar 2 |
|
EEG profile of litoxetine after single and repeated administration in healthy volunteers. | 1994 Feb |
|
The psychomotor and cognitive effects of litoxetine in young and middle aged volunteers. | 1995 Aug |
|
The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors. | 1995 Mar |
|
Pharmacological characterization of the cloned human 5-hydroxytryptamine transporter. | 1996 May 3 |
|
Influence of fluoxetine and litoxetine on 5-HT4 receptor-mediated relaxation in the rat isolated oesophagus. | 1999 |
|
Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. | 2002 Apr |
|
Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. | 2009 Apr 15 |
|
Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. | 2009 Oct 15 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8562293
2.5 mg, 5 mg, 10 mg, 25 mg or placebo twice daily on days 1-4 and once on day 5
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:51:41 GMT 2023
by
admin
on
Fri Dec 15 15:51:41 GMT 2023
|
Record UNII |
9980ST005G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6662
Created by
admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
|
PRIMARY | |||
|
SUB08536MIG
Created by
admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
|
PRIMARY | |||
|
86811-09-8
Created by
admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
|
PRIMARY | |||
|
9980ST005G
Created by
admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
|
PRIMARY | |||
|
CHEMBL471036
Created by
admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
|
PRIMARY | |||
|
Litoxetine
Created by
admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
|
PRIMARY | |||
|
C66021
Created by
admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
|
PRIMARY | |||
|
100000082545
Created by
admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
|
PRIMARY | |||
|
C057048
Created by
admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
|
PRIMARY | |||
|
DB15038
Created by
admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
|
PRIMARY | |||
|
DTXSID30235828
Created by
admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
|
PRIMARY | |||
|
65650
Created by
admin on Fri Dec 15 15:51:41 GMT 2023 , Edited by admin on Fri Dec 15 15:51:41 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |